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Abstract
Background: The optimal duration of preventive therapy for tuberculosis (TB) among HIV-infected persons in TB-endemic
countries is unknown.
Methods: An open-label randomized clinical trial was performed and analyzed for equivalence. Seven hundred and twelve
HIV-infected, ART-naı¨ve patients without active TB were randomized to receive either ethambutol 800 mg and isoniazid
300 mg daily for six-months (6EH) or isoniazid 300 mg daily for 36-months (36H). Drugs were dispensed fortnightly and
adherence checked by home visits. Patients had chest radiograph, sputum smear and culture performed every six months,
in addition to investigations if they developed symptoms. The primary endpoint was incident TB while secondary endpoints
were all-cause mortality and adverse events. Survival analysis was performed on the modified intent to treat population (m-
ITT) and rates compared.
Findings: Tuberculosis developed in 22 (6.4%) of 344 subjects in the 6EH arm and 13 (3.8%) of 339 subjects in the 36H arm
with incidence rates of 2.4/100py (95%CI- 1.4–3.5) and 1.6/100py (95% CI-0.8–3.0) with an adjusted rate ratio (aIRR) of 1.6
(0.8–3.2). Among TST-positive subjects, the aIRR of 6EH was 1.7 (0.6–4.3) compared to 36H, p = 0.8. All-cause mortality and
toxicity were similar in the two arms. Among 15 patients with confirmed TB, 4 isolates were resistant to isoniazid and 2 were
multidrug-resistant.
Interpretation: Both regimens were similarly effective in preventing TB, when compared to historical incidence rates.
However, there was a trend to lower TB incidence with 36H. There was no increase in isoniazid resistance compared to the
expected rate in HIV-infected patients. The trial is registered at ClinicalTrials.gov, NCT00351702.
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Introduction
Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
are the two leading infectious causes of death globally, with TB
being the most common cause of death among HIV-infected
persons in the developing world [1,2]. Although antiretroviral
therapy (ART) reduces the risk of TB substantially, TB remains
the most important cause of mortality and morbidity in patients on
ART [3,4]. India has a high burden of TB with an estimated
prevalence of latent TB infection (LTBI) of 50%, an annual risk of
TB infection of 1?5% and an estimated 1?96 million new cases of
TB annually [5,6]. Of the approximately 2?4 million people living
with HIV in India, the incidence of TB has been reported to be as
high as 6?9 cases/100 person-years (PY) [7,8].
In the pre-ART era, several clinical trials demonstrated a
reduction in TB incidence in HIV-infected patients with the
administration of TB preventive therapy [9–11]. A recent meta-
analysis found that isoniazid preventive therapy (IPT) reduces the
risk of active TB by 33% overall and by 64% among adults with a
positive tuberculin skin test (TST) [12]. The World Health
Organization’s (WHO) recommended regimen for TB preventive
therapy in adolescents and adults living with HIV is isoniazid (H)
300 mg daily for six months [13]. Shorter regimens (e.g. two
months of rifampicin and pyrazinamide) have been shown to be
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non-inferior, however rates of adverse effects were somewhat
higher [14,15]. While WHO recommended the use of TB
preventive therapy for HIV-infected persons as early as 1998,
very few national programmes have implemented this policy
[16,17]. Challenges faced by programmes in implementing IPT
services include the difficulty in excluding active TB disease with
certainty prior to initiation of IPT, poor adherence, potential
emergence of drug resistance, uncertainty about the optimal
length and composition of regimen and the cost-effectiveness of
such an approach in high TB prevalence settings [18].
To determine the optimal duration of TB preventive therapy
regimen in HIV-infected persons living in India, a TB-endemic
country, we undertook a randomized clinical trial comparing six
months of Isoniazid (H) and ethambutol (E) with 36 months (proxy
for lifelong) of isoniazid. The rationale for the choice of isoniazid
and ethambutol was to preserve rifampicin for chemotherapy and
avoid the adverse effects of pyrazinamide whilst providing anti-
tuberculosis activity in patients latently infected with isoniazid-
resistant mycobacteria. While no previous studies have tested the
EH combination, this was chosen in view of the 10–20%
prevalence of isoniazid resistance among HIV-infected TB
patients in India. [19,20]. We hypothesized that the efficacy of a
6-month two drug combination (6EH) would be equivalent to
using a single drug for a longer regimen (36H), with no more than
5% difference in cumulative (3-year) TB incidence between the
two regimens, and that both would decrease TB incidence by at
least 50% compared to historical data from the same setting [8].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Figure 1. Trial Profile of all patients.
doi:10.1371/journal.pone.0047400.g001
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Ethics Statement
This study was approved by the Scientific Advisory Committee
and Institutional Ethics Committee of Tuberculosis Research
Centre, Chennai. A written informed consent was obtained from
all the study participants before enrollment to the study.
Study Design and Participants
This was a prospective, parallel arm, open label randomized
controlled clinical trial conducted at the Tuberculosis Research
Centre (TRC) clinics in Chennai and Madurai, southern India.
Recruitment occurred between March 2001 and October 2005.
HIV-infected individuals .18 years, without past or current
evidence of TB disease, living within the defined area of intake,
consenting to all the terms and conditions of the trial and fulfilling
the laboratory criteria (normal chest radiograph, haemoglobin
$70 g/L, granulocyte count $1?16109/L, platelet count
$1006109/L, serum alanine amino transferase #2?5 times the
upper limit of normal, serum creatinine concentration ,1?1 mg%
and random plasma sugar ,140 mg%) were enrolled.
Randomisation and masking
Randomisation was performed using computer-generated ran-
dom allocation sequences in permuted blocks of eight, stratified by
TST status (, or .5 mm). The group assignment list was
generated centrally before the start of the trial. Sequentially
numbered, sealed, opaque envelopes containing the study group
assigned were prepared independently and opened at the patient
care facility at the time of allocation by a different group of
statisticians.
Procedures
Patients had a complete physical examination, sputum smear
and culture (two overnight and one spot specimen), chest
radiograph, tuberculin skin test (TST) and blood investigations.
Sputum smears were examined by fluorescence microscopy,
processed by the modified Petroff’s method and cultured on
Lowenstein-Jensen medium, with species identification and drug
susceptibility testing [21]. Chest radiographs were read by two
physicians independently and a third reader for discordant results.
A TST was performed with 1TU PPD RT23 and read after 48–
72 hours, with an induration of $5 mm considered positive.
Additional baseline investigations included complete blood count
(automated hematology analyzer ABX, France), CD4 count
Table 1. Demographic Details of m-ITT Population (n = 683).
6EH (n=344) 36H (n=339)
Age (Mean 6 SD), years 29?967 30?267
Weight (Mean 6 SD), kgs 51610 50610
Females n (%) 218 (63) 212 (63)
Age distribution n % n %
,25 years 106 30 97 29
25–40 years 208 61 216 64
.40 years 30 9 26 7
TST induration n % n %
,5 mm 203 59 207 61
5–10 mm 29 8 22 7
.10 mm 112 33 110 32
TST induration (Mean 6 SD), mm 7?6 9?6 7?2 9?3
CD4 Count, Median (IQR),* cells/mm3 326 (208–520) 324 (197–463)
CD4 count distribution n % n %
,100 cells/mm3 27 9 28 9
100–200 cells/mm3 51 16 56 18
201–350 cells/mm3 90 28 91 28
351–500 cells/mm3 62 20 68 21
.500 cells/mm3 86 27 77 24
*CD4 counts were available for 316 in 6EH and 320 patients in 36H arms
respectively.
doi:10.1371/journal.pone.0047400.t001
Table 2. Crude rates and adjusted incidence rate ratios for TB incidence and death, in ITT, m-ITT (excluding culture positive cases
at baseline) and per-protocol population.
TB Death
Number of
cases
Crude rate/100py
(95% CI) aIRR (95% CI)
Number of
deaths
Crude Rate/100py
(95% CI) aIRR (95% CI)
ITT
6EH (357) 2.33
(1.36–3.31)
1.15
(0.68–1.95)
2.65
(1.61–3.69)
1.20
(0.66–2.18)
36H (355) 1.39
(0.63–2.14)
ref 2.13(1.20–3.07) Ref
m-ITT
6EH (344) 22 2?44
(1.42–3.46)
1.59
(0.79–3.21)
25 2?77
(1.68–3.86)
1.22
(0.65–2.29)
36H (339) 13 1?55
(0.79–3.03)
1.0 (reference) 20 2?21
(1.24–3.18)
1.0 (reference)
Per protocol
6EH (320) 18 2.03
(1.09–2.97)
1.60
(0.73–3.49)
25 2.82
(1.72–3.93)
1.21
(0.67–2.27)
36H (299) 11 1.30
(0.53–2.07)
1.0 (reference) 20 2.37
(1.33–3.41)
1.0 (reference)
doi:10.1371/journal.pone.0047400.t002
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(FACSort flow cytometer, Becton Dickinson, USA), HIV viral load
(Roche Amplicor automated viral load monitor, V1?5, Germany),
renal and liver function tests, and random blood sugar (automated
analyzer, Olympus Corporation, Tokyo, Japan). Urine was
examined for albumin, sugar and acetyl isoniazid.
Regimens used were isoniazid 300 mg and ethambutol 800 mg
daily for six months (6EH) or isoniazid 300 mg daily for 36 months
(36H). Subjects in both study groups received 10 mg of pyridoxine
daily during the treatment period and co-trimoxazole DS one
tablet daily if CD4 count was ,250 cells/mm3 for the entire
period. From April 2004 onwards, patients were referred to the
nearest government centre for evaluation and initiation of free
ART if eligible (Stage III/IV disease or CD4 ,250 cells/mm3).
Study medications were dispensed fortnightly for self-adminis-
tration. During these visits, patients were asked to return the
empty packets as well as any unused tablets. Patients expressing
new symptoms were referred to the study physicians to rule out
drug toxicity and/or active TB disease. Additionally, patients were
monitored every three months for clinical status, adverse effects,
adherence and the development of active TB disease. Details of
adverse drug reactions and their management were recorded on a
standardized toxicity form [22]. Adherence was assessed by pill
counts of returned drugs, examination of spot urine samples for
acetyl isoniazid and home visits done on random days approxi-
mately once in two weeks. Mycobacterial smear and culture (on
two sputum specimens), chest radiograph, CD4 count, and liver
and renal function tests were performed every six months and
when clinically indicated. All patients were followed for 36 months
post randomization.
Endpoints
The primary endpoint was the development of pulmonary or
extra-pulmonary TB during the study period. TB was classified as
definite (positive mycobacterial culture) or probable (clinical/
radiographic/histopathologic/biochemical features) based on re-
view by a panel blinded to study assignment. Patients who
developed active TB were treated with the standard national re-
treatment regimen if they had received .1 month of study
medications [23]. The secondary endpoints were all-cause
mortality and adverse events. Cause of death was ascertained by
verbal autopsy in case of death at home or hospital records in case
of death in a health care facility and was classified as due to TB or
to a non-TB cause.
Statistical Analysis
The sample size was calculated anticipating a 50% reduction in
TB incidence from historical data from a demographically similar
cohort [8]. Assuming that the 36H regimen would reduce
cumulative TB incidence over 3 years from 20% to 10%, an
equivalence margin for 6EH of 5%, with a beta of 0?20, an alpha
of 0?05, the number of patients required per arm was 325. This
was increased by 10% to account for default/death making a final
sample size of 350/arm. Data were analyzed using SPSS version
14. The primary analysis was a modified intent to treat analysis
(m-ITT) excluding only those who had culture confirmed TB at
Table 3. TB incidence and mortality rate among TST positive and negative subjects, by regimen (mITT population) and per
protocol analysis.
mITT analysis
TB incidence/100 py
(95%CI) aIRR (95% CI)
Mortality/100 py
(95%CI) aIRR (95% CI)
TST.5 mm 6EH (n = 141) 3.18 (1.38–4.97) 1.66 (0.63, 4.30) 2.91 (1.19–4.63) 1.51(0.56,4.02)
36H (n = 132) 1.81 (0.69–3.04) Reference 2.53 (1.21–3.85) Reference
TST#5 mm 6EH (n = 203) 1.94 (0.5–3.38) 1.48 (0.55, 3.96) 1.94 (0.5–3.38) 1.10 (0.50,2.41)
36H (n = 207) 1.23 (0.32–2.13) Reference 2.28 (1.04–3.51) Reference
Per protocol analysis
TST.5 mm 6EH (n = 131) 2.80 (1.06–4.70) 1.57 (0.50, 4.9) 3.08(1.26–4.89) 1.43 (0.53,3.8)
36H (n = 116) 1.84(0.37–3.32) Reference 2.15(0.56–3.74) Reference
TST#5 mm 6EH (n = 189) 1.52 (0.47–2.57) 1.51 (0.53, 4.3) 2.65(1.26–4.04) 1.04 (0.48, 2.29)
36H (n = 183) 0.96 (0.12–1.81) Reference 2.51(1.14–3.87) Reference
doi:10.1371/journal.pone.0047400.t003
Table 4. Crude TB incidence and death rates and adjusted incidence rate ratios: stratified analysis on m-ITT population.
TB Death
Cruderate/100 py
(95% CI) aIRR (95% CI)
Crude rate/100py
(95% CI) aIRR (95% CI)
Male 2?35 (1?12–3?58) 1?3 (0?64–2?59) 5?20 (3?37–7?03) 3?7 (1?87–7?15)
Female 1?31 (0?65–1?97) 1.0 (reference) 1?22 (0?58–1?86) 1.0 (reference)
CD4#200 cells/mm3 4?07 (2?07, 6?06) 4?8 (2?29–9?85) 5?34 (3?05, 7?62) 2?9 (1?54–5?76)
CD4.200 cells/mm3 0?97 (0?44, 1?50) 1.0 (reference) 1?80 (1?08, 2?51) 1.0 (reference)
doi:10.1371/journal.pone.0047400.t004
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baseline. Intent to treat analysis including all randomized patients
and per-protocol analysis restricted to patients fulfilling all
eligibility criteria, with treatment adherence of .80%, survival
without TB beyond 6 weeks after randomization and with
complete follow-up were also performed. The effect of treatment
on the rate of TB was assessed using person-time from date of
randomization until the earliest endpoint, i.e. documented TB
disease or censoring (due to death, loss to follow-up or the end of
the study at 36 months). Kaplan-Meier survival plots were used to
calculate the crude effect of both regimens on TB-free survival and
mortality and compared using the log rank test. Cox proportional
hazards models were used to obtain an estimate of the effect of the
regimens on the primary endpoint, after adjusting for potential
confounders (sex, CD4 count and TST status) with ART as a time-
dependent covariate. The main measures of effect used were rate
ratios with confidence intervals.
The Accelerated Failure Time model was used to compare the
curves wherever the hazards were found crossing. Equivalence was
accepted if the point estimate and confidence interval was within
the equivalence margin (5% around the cumulative 3-year
incidence for 36H).
Berger-Exner test was performed taking the treatment response
(development of active tuberculosis or not) as the dependent
variable and the probability of predicting the concealed treatment
assignment as well as the order of allocation within the block size
of eight, as independent variables, along with other baseline
covariates. The Berger-Exner test was used in conjunction with the
comparison of baseline covariates, as the former was more
sensitive to unobservable bias and the latter was more sensitive
to observable selection bias [24].
Preliminary results were presented at the Conference on
Retroviruses and Opportunistic Infections, February 2010, San
Francisco [25]. The trial was registered in the NIH trial registry
(NCT00351702).
Results
Of the 1,095 individuals screened, 712 were enrolled and
randomized to the study regimens (ITT population), Figure 1.
Berger Exner’s showed that there was no prediction of outcome by
the allocation probability within treatment groups ruling out
selection bias. Twenty-nine patients were excluded because of
positive M.tuberculosis baseline sputum cultures, leaving 683
patients in the modified (m-ITT) population. Baseline character-
istics were similar in the two arms: majority of patients were ,40
years of age, 63% were females and nearly half had a CD4 count
.350 cells/mm3 (Table 1). Eighty eight percent (299/339) of
patients in the 36H and 93% (320/344) in the 6EH arm
comprised the per-protocol population (trial profile in supplemen-
tary appendix 1). The total follow-up period was 885 PY (median
2.6 years) in the 6EH arm and 844 PY (median 2.5 years) in the
36H arm. 169 patients started ART, mainly during the third year
of follow-up – 76 patients in the 6EH arm accounting for 152 PY
and 93 patients in 36H arm accounting for 172 PY of exposure
(p = 0.4).
Tuberculosis developed in 22 (6.4%) of 344 subjects in the 6EH
arm and 13 (3.8%) of 339 patients in the 36H arm with incidence
rates of 2.4/100py (95% CI 1.4–3.5) and 1.6/100py (0.8–3.0)
respectively; adjusted rate ratio 1.6 (95% CI 0.8–3.2). The two
rates were equivalent statistically. Rates of TB incidence, death
and adjusted incidence rate ratio (aIRR) for the total group and
among TST positive and TST negative subjects are provided in
Table no. 2 and 3 respectively. No statistically significant
differences were observed between the two regimens by ITT, m-
ITT or per-protocol analyses. Table 4 shows the TB incidence and
death rates and rate ratios stratified by sex and CD4 count.
Patients who developed TB did so at a median of 12 months -
overall, 34% of cases occurred in the first six months, 46% in the
next twelve months and 20% thereafter. Fifteen patients had
bacteriologically confirmed TB (10 in the 6EH arm and 5 in the
36H arm), most had some symptoms (cough, fever or malaise) at
the time of TB breakdown (supplementary appendix-2).
Figure 2. Kaplan-Meier curves showing cumulative probability of survival without TB and death over 36 months by regimen, TST
status, CD4 count and sex. The four top panels show cumulative survival without TB over 36 months by regimen (6EH versus 36H, ns), TST
(,5 mm versus .5 mm, ns), CD4 count (,200 versus .200 cells/mm3, p,0.001) and sex (female versus male, p = 0.05). The four bottom panels
show cumulative mortality over 36 months by regimen (6EH versus 36H, ns), TST (,5 mm versus .5 mm, ns), CD4 count (,200 versus .200 cells/
mm3, p,0.001) and sex (female versus male, p,0.001).
doi:10.1371/journal.pone.0047400.g002
Table 5. Causes of death.
Cause of Death 6EH (n=25) 36H (n=20)
CNS complications of HIV 4 4
CVA (cerebral infarct) 2 1
Diarrhoea with wasting 4 3
Opportunistic Infections 3
(Pneumonia-1, Cryptococcal meningitis-1,
Disseminated M. avium disease-1)
3
(Pneumonia-1, Pneumocystis jirovecci pneumonia -1,
Disseminated Candidiasis -1)
AIDS-related complications 5 1
Others 5
(Unknown-3, CA Lung-1, Suicide-1)
8
(Unknown-2, Myocardial infarction-3, Road traffic
accident-1,CA larynx-1, Suicide-1)
TB (probable) 2 0
doi:10.1371/journal.pone.0047400.t005
Trial of TB Preventive Therapy in HIV
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The incidence of bacteriologically confirmed TB among TST
positive individuals in 6EH regimen and 36H regimen was 1.9/
100py (1.8–12.2) and 0.8/100py (0.62–8.8), with the incidence
rate ratio being 1.54 (95% CI 0.19–2.88) p = 0.63. Of the 15
culture-confirmed cases, 8 had M.tuberculosis susceptible to all first-
line drugs, 4 were resistant to isoniazid, 1 to streptomycin, 1 to
isoniazid and rifampicin and 1 to streptomycin, isoniazid and
rifampicin. In 20 patients (12 in the 6EH arm and 8 in the 36H
arm) the diagnosis of TB was based on clinical, radiographic or
histopathologic evidence (supplementary appendix 3).
Twenty-five patients in the 6EH arm (2?8/100PY, 95%CI 1?7–
3?9) and 20 patients in the 36H arm (2?2/100PY, 95%CI 1?2–3?2)
died during the 36-months. There was no difference in mortality
by regimen. Death rate was significantly higher among males and
among patients with CD4 count below 200 cells/mm3 but similar
in individuals with positive and negative TST status (Figure 2A &
2B, Tables 3 & 4). The median CD4 at the time of death was 66
(IQR 36–132) and 73 (IQR 40–308) cells/mm3 in the 6EH and
36H arms, respectively. Two patients in the 6EH arm had been
initiated on ATT by the treating physician shortly before death
and were therefore considered as ‘‘probable TB deaths’’, though
no confirmatory evidence was available. Since death was the first
reported event, these patients have been included in the mortality
analysis but not as incident TB cases. The most common cause of
death was progressive HIV disease with complications/opportu-
nistic infections (Table 5).
Overall, the study drugs were well tolerated, with 3% of patients
reporting grades I–IV toxicity relating to treatment (22 adverse
events) (Table 6). Three patients in each arm had increased
bilirubin levels; drugs were temporarily withheld and successfully
re-introduced after liver function tests returned to normal. Two
patients in the 36H arm had severe peripheral neuropathy
necessitating permanent withdrawal of isoniazid, one at the 23rd
month and the other at the 33rd month.
Discussion
A six-month regimen of isoniazid and ethambutol (6EH) and a
36-month regimen of isoniazid alone (36H), considered as proxy
for life-long therapy, were equally effective in preventing active TB
among HIV-infected individuals in India. The incidence rates
were substantially lower (by 65% and 78% respectively) than
observed in a previous cohort study of HIV-infected patients in the
same geographic area [8]. While TB incidence was approximately
40% lower with 36H than with the 6EH regimen, this difference
was not statistically significant However, due to the lower than
expected event rate in the trial, the power of the study to detect a
difference of .5% cumulative TB incidence (or 1.6%/year) was
65%, limiting the strength of our conclusions. Results using per-
protocol, ITT and modified intent-to-treat analysis were however
consistent, suggesting that a difference between arms was not
attenuated by decreased adherence in the 36H arm. Considering
only confirmed TB, the 36H group had 5 cases versus 10 in 6EH,
suggesting that the longer regimen could have been more effective,
but the difference was not statistically significant. However, as TB
in HIV-infected persons is often difficult to confirm by sputum
culture, clinically diagnosed cases also need to be considered for
analysis for extrapolation into real life settings.
The issue of optimal duration of prophylactic regimen has
recently been addressed in two studies. Similar to our study,
Martinson et al showed that while there was a lower incidence rate
of TB in their continuous Isoniazid arm, this was not statistically
significant compared to the shorter regimen of 6 months of
Isoniazid. [26]. In contrast, a study comparing six-months versus
36-months of IPT in Botswana reported a significantly greater
efficacy with the longer regimen, an effect which was more
pronounced among TST-positive individuals [27]. Major differ-
ences between the Botswana and this trial include a higher TB
incidence, open labeled design, use of 1 TU PPD, lower power of
the study (India) versus double-blind placebo controlled design, use
of 5TU PPDRT23, larger number of TST+ individuals and
greater use of ART in the Botswana study. These factors could
potentially account for the contrasting results.
Both regimens in our study were well tolerated, with only two
patients discontinuing therapy due to severe peripheral neurop-
athy (both in the longer regimen). In one meta-analysis, the
efficacy of prophylactic regimens was similar irrespective of drug
type, frequency or duration of treatment. However, short course
multidrug regimens (especially with pyrazinamide) were much
more likely to require discontinuation due to toxic effects [28].
Incidence rates of TB were not statistically significantly different
in the two regimens when analysis was restricted to TST positive
individuals, considering overall TB as well as bacteriologically
confirmed cases. However TB rates in the 36H arm were lower
compared to 6EH both among TST positive and negative
subjects, suggesting that the longer regimen may protect both
against exogenous infection as well as reactivation of latent disease
[29]. Our previous findings that TST (using 1TU PPD) has poor
sensitivity in detecting latent TB in patients with HIV suggest that
the role of TST in screening patients for TB preventive therapy
needs to be examined further perhaps using higher strengths of
PPD [30].
The duration of protective effect of TB preventive therapy for
HIV-infected patients ranges from 12 months to three years and
appears to be higher with multi-drug therapy [12,28,31,32]. In the
current study also, the median time to develop TB among subjects
in the 6EH arm was 12 months from the end of treatment.
Four patients developed isoniazid resistant TB while two had
MDR-TB. This is consistent with the number of expected drug
resistant incident TB cases (six for isoniazid and 1?6 for MDRTB)
extrapolated from previous data in a similar population without
exposure to TB preventive therapy (supplementary appendices 4a
and 4b) [19]. Successful preventive treatment of isoniazid
susceptible latent infections would leave mainly resistant infections
to re-activate, suggesting that re-treatment regimens should be
employed for patients who develop TB on IPT. Previous reports
including one systematic review did not observe an increased risk
of drug resistant TB after preventive therapy (risk ratio 1.45, 0.85–
Table 6. Adverse Drug Reactions (based on common toxicity
criteria manual [22]).
6EH (n=344) 36H (n=339)
Grade
I/II
Grade
III
Grade
IV
Grade
I/II
Grade
III
Grade
IV
Arthralgia 1 - - - 1 -
Nausea, vomiting
gastritis
2 1 - 1 - -
Jaundice - - 3# - 2# 1#
Neuropathy 2 - - 1 1 2*
Cutaneous 2 - - 1 1# -
Any ADR 11 11
#- Drugs temporarily withheld and re-introduced (n = 7).
*Drug permanently discontinued (n = 2, one at 23rd month, one at 33rd month).
doi:10.1371/journal.pone.0047400.t006
Trial of TB Preventive Therapy in HIV
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2.47), but numbers of patients in individual studies were small
[33,34].
In the current study, mortality rates were not statistically
different between the two arms. Most patients died of complica-
tions of advanced AIDS before they could access ART.
Retrospective observational studies in South Africa and Brazil
have reported an additive benefit of IPT and ART [35,36]. The
intensive screening for TB that is part of the package of care
recommended for patients initiating ART and treatment of active
TB patients are other co-benefits of enrolment in an IPT program,
likely to lead to mortality reductions [37]. Given the updated
WHO recommendations for initiation of ART at a CD4 count of
#350 cells/mm3, we anticipate that the efficacy of IPT will
improve as patients gain wider access to ART.
Among the strengths of our study are high rates of adherence
and follow-up due to intensive monitoring strategies in both
therapy arms, thorough TB screening at routine intervals to
minimize detection bias, and consistent results between the ITT,
modified intention-to-treat and per-protocol analyses. Though
ours was an open label trial, the Berger-Exner test showed that
there was no unobservable selection bias. The results should be
interpreted with caution, however, in light of certain limitations.
Firstly, the impact of the ethambutol in the 6EH arm is not clearly
understood, especially because of the lack of a 6H arm. The lack of
ethambutol resistance in active TB cases and low risk of drug
toxicity in both arms makes it an ideal companion drug. Further
study will be required to assess the efficacy advantage of equal
length TB preventive therapy regimens with isoniazid plus
ethambutol over isoniazid alone. The absence of a concurrent
placebo or control arm was substituted by the use of historical data
from the same setting, though this is obviously not ideal. Thirdly,
at completion, our trial was underpowered to find a difference in
protective effect, especially in the analysis stratified by TST status.
Finally, as noted above, limited access to ART in the first several
years of the trial resulted in increased TB risk and mortality,
possibly leading to underestimation of the benefit of TB preventive
therapy.
The evidence from our trial suggests that both 6 and 36-month
preventive therapy regimens are safe and highly effective (with a
trend to higher efficacy with the longer regimen) in preventing TB
among HIV-infected individuals in India. Policy makers can make
a choice based on feasibility and other logistic considerations from
a public health standpoint but it is clear that this intervention
should be considered a priority for inclusion in the package of care
and support for HIV-infected patients in TB-endemic countries.
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